在脊柱和腹筋肌肉缩 (SBMA) 的认知和行为参与:一个系统的审查
Giulia De Luca1, Edoardo Nicolò Aiello1, Arianna Moreschi1
1Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Milano, Italy.
Amyotrophic lateral sclerosis & frontotemporal degeneration
|March 13, 2026
概括
在脊柱和腹筋肌肉缩 (SBMA) 中对认知和行为变化的证据有限. 一些SBMA患者可能表现出执行功能障碍,这表明潜在的额叶参与.
科学领域:
- 神经科学是一个神经科学.
- 神经学 神经学
- 遗传学 是一个遗传学.
背景情况:
- 脊柱和柱状肌肉缩 (SBMA) 是一种罕见的遗传性神经退行性疾病.
- 了解SBMA的认知和行为影响对于全面的患者护理至关重要.
研究的目的:
- 系统地审查SBMA患者认知和行为变化的现有证据.
- 综合从案例报告,系列和小组研究中得出的发现.
主要方法:
- 根据PRISMA 2020指南进行文献搜索和审查.
- 包括病例报告/系列和小组研究,详细介绍SBMA患者的神经心理特征.
- 分析了11项涉及151名SBMA患者的研究的数据.
主要成果:
- 在案例研究中,60%的患者报告了神经心理参与,其中一些患者表现出类似痴呆症的症状.
- 组研究显示出混合的结果,有些人发现与对照组相比没有认知差异.
- 群体研究中的认知缺陷主要影响执行功能,注意力,记忆和视觉空间技能.
结论:
- 目前关于SBMA认知和行为变化的证据稀缺且不一致.
- 一部分SBMA患者可能表现出disexecutive症状.
- 研究结果表明,SBMA中可能涉及额头系统.
相关概念视频
Myasthenia Gravis: Overview and Treatment
3.3K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.3K
Cross-bridge Cycle
124.2K
As muscle contracts, the overlap between the thin and thick filaments increases, decreasing the length of the sarcomere—the contractile unit of the muscle—using energy in the form of ATP. At the molecular level, this is a cyclic, multistep process that involves binding and hydrolysis of ATP, and movement of actin by myosin.
124.2K
Parkinson's Disease: Overview
2.3K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.3K


